Key result
Low-dose aspirin (60 mg daily) did not significantly affect the primary endpoints of proteinuric eclampsia, intrauterine growth retardation, stillbirth, or neonatal death in at-risk pregnant women.
Null result provides no support for low-dose aspirin in at-risk pregnancies; leaves open efficacy questions for randomized trials.
increase recruitment are imperative.One recent landmark American trial took four years to enrol 129 patients"; over the same period some 40 000 new cases of oesophageal cancer were diagnosed in the United States.
No takes yet. Share an insight, caveat, or question.
Lawrence J. Beilin (1994) conducted an editorial in Risk of pre-eclampsia or intrauterine growth retardation (n=9,354). Aspirin vs. Placebo was evaluated on Proteinuric eclampsia, intrauterine growth retardation, stillbirth, or neonatal death. Low-dose aspirin (60 mg daily) did not significantly affect the primary endpoints of proteinuric eclampsia, intrauterine growth retardation, stillbirth, or neonatal death in at-risk pregnant women.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: